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Technology to overcome clinical inertia in insulin therapy?
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Why does this happen? There are some obvious challenges. Diabetes care is frequently provided in busy generalist/ primary care services with numerous competing time demands. There may be a reluctance by providers and patients to move from oral to injectable therapy (whether insulin or GLP-1 agonists) and a lack of time, confidence and diabetes education resources available to support training and dose titration. With insulin, there may be additional specific concerns about potential weight gain and risk of hypoglycaemia. 
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Glycaemic control improved more in the group using the d-Nav system than in the control group (HbA1c decrease of 11 vs 3 mmol/mol or 1·0 vs 0·3%). On average, the algorithm adjusted insulin doses 1·1 times weekly- a frequency of adjustment which would be pragmatically unachievable in routine practice. As expected, this was achieved with a marked increase in insulin administration in the group using the d-Nav with final doses being over 60% greater than the control group. Despite higher insulin doses, weight gain was minimal and the overall rates of hypoglycaemia were low in both groups and no greater in the titration group. 

Overall, given that the system markedly increased insulin doses, it is interesting that there was no obvious increase in hypoglycaemia. Unlike many other current diabetes studies, continuous glucose monitoring was not performed so hypoglycaemia data are largely based on capturing low glucose values during self-monitoring. Of note, the group randomised to use the d-Nav device performed more glucose tests, perhaps reflecting the users’ perceived value of the system. Importantly for safety, the algorithm can either decrease or increase doses and about 15% of dose titrations during the study were dose reductions. The population studied here had relatively low rates of hypoglycaemia though and an important question for more widespread future use would be whether automated insulin dose titration would result in increased hypoglycaemia in those at higher baseline risk. 
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As expected in the context of a clinical trial, both groups had frequent contact with study team with seven face to face or telephone contacts over the six month period. The authors are careful to describe the intervention as d-Nav delivered with health care professional support. During contacts, study teams checked overall wellbeing and health changes etc. but also assessed use of the device and could also suggest alterations in insulin doses. In the real world, if this was an essential requirement for success of the system, this frequency of contact would be challenging for many services.  

Finally and importantly, how comfortable would patients and clinical teams be in allowing an algorithm to manage insulin dose titration? Generally, participants in this study were comfortable with receiving dose advice from the device. The world of type 1 diabetes with far greater complexity of insulin dosing is already moving rapidly towards automated closed loop insulin delivery.7 Faced with increasing pressures and demands on primary care, it seems likely that there is a significant niche for technology to help in type 2 diabetes. 
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